Cost-Effectiveness of Sarilumab Versus Adalimumab for Treating Patients with Active Rheumatoid Arthritis- A Markov Model Assessment

May 1, 2018, 00:00
10.1016/j.jval.2018.04.1338
https://www.valueinhealthjournal.com/article/S1098-3015(18)31641-3/fulltext
Title : Cost-Effectiveness of Sarilumab Versus Adalimumab for Treating Patients with Active Rheumatoid Arthritis- A Markov Model Assessment
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31641-3&doi=10.1016/j.jval.2018.04.1338
First page :
Section Title :
Open access? : No
Section Order : 592
Categories :
Tags :
Regions :
ViH Article Tags :